Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Biosimilars Specialty Channel

News
Proposed Bevacizumab Biosimilar BAT1706 Found Equivalent to Reference Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer
11/22/2023
According to a phase 3 trial, the proposed bevacizumab biosimilar BAT1706 was found equivalent to reference biosimilar for the treatment of patients with advanced nonsquamous non-small cell lung cancer.
According to a phase 3 trial, the proposed bevacizumab biosimilar BAT1706 was found equivalent to reference biosimilar for the treatment of patients with advanced nonsquamous non-small cell lung cancer.
According to a phase 3 trial,...
11/22/2023
Oncology
News
Pertuzumab Biosimilar QL1209 Demonstrated Equivalent Efficacy, Safety to Reference Pertuzumab Among Patients With HER2-Positive Breast Cancer
11/06/2023
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study,...
11/06/2023
Oncology
Quiz
Patients’ Perceptions of Biosimilars
10/23/2023
True or False: According to a systematic review, patients generally lack knowledge about biosimilars and rely on physicians, pharmacists, medicine agencies, academia, and patient associations for information.
True or False: According to a systematic review, patients generally lack knowledge about biosimilars and rely on physicians, pharmacists, medicine agencies, academia, and patient associations for information.
True or False: According to a...
10/23/2023
Oncology
News
Bevacizumab Biosimilar Efficacy, Safety for Patients With Metastatic Colorectal Cancer
10/10/2023
According to real-world data, the bevacizumab biosimilar, bevacizumab-awwb, was found to be as effective and safe as the bevacizumab reference product for patients with metastatic colorectal cancer.
According to real-world data, the bevacizumab biosimilar, bevacizumab-awwb, was found to be as effective and safe as the bevacizumab reference product for patients with metastatic colorectal cancer.
According to real-world data,...
10/10/2023
Oncology
News
Docetaxel-PM Plus Trastuzumab Biosimilar Showed Antitumor Activity Among Patients With HER2-Positive Salivary Duct Carcinoma
10/10/2023
According to a phase 2 trial, combination docetaxel-PM and trastuzumab-pkrb demonstrated antitumor activity among patients with HER2-positive salivary duct carcinoma.
According to a phase 2 trial, combination docetaxel-PM and trastuzumab-pkrb demonstrated antitumor activity among patients with HER2-positive salivary duct carcinoma.
According to a phase 2 trial,...
10/10/2023
Oncology
News
Patients Report Satisfaction With Biosimilar Treatment, But Demonstrate Lack of Overall Knowledge
09/11/2023
According to a systematic review, patients are satisfied with biosimilar treatments but have limited knowledge about biosimilars, a lack of which can affect their perceptions of the clinical effects and regulation process.
According to a systematic review, patients are satisfied with biosimilar treatments but have limited knowledge about biosimilars, a lack of which can affect their perceptions of the clinical effects and regulation process.
According to a systematic...
09/11/2023
Oncology
News
Biosimilar Rituximab Plus CHOP Effective, Well-Tolerated Among Patients With Previously Untreated CD20-Positive DLBCL
09/07/2023
The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.
The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.
The rituximab biosimilar,...
09/07/2023
Oncology
News
Serplulimab Plus Bevacizumab Biosimilar Showed Efficacy, Safety Among Patients With Hepatocellular Carcinoma
09/05/2023
According to a results from a phase 2 study, serplulimab plus HLX04, a bevacizumab biosimilar, showed promising antitumor activity and manageable safety among patients with previously treated advanced hepatocellular carcinoma.
According to a results from a phase 2 study, serplulimab plus HLX04, a bevacizumab biosimilar, showed promising antitumor activity and manageable safety among patients with previously treated advanced hepatocellular carcinoma.
According to a results from a...
09/05/2023
Oncology
News
Trastuzumab Biosimilar Plus Paclitaxel Shows Promise for Patients With HER2-Positive Recurrent or Metastatic Urothelial Carcinoma
08/04/2023
In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.
In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.
In a phase 2 trial, the...
08/04/2023
Oncology
News
Bevacizumab Biosimilar Demonstrated Similar Efficacy, Safety as Reference Product Among Patients With Metastatic Colorectal Cancer
07/31/2023
The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.
The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.
The bevacizumab biosimilar,...
07/31/2023
Oncology
News
Bevacizumab Biosimilar Candidate TAB008 Comparable to Reference Bevacizumab for Patients With Locally Advanced, Metastatic EGFR Wild-Type Non-Squamous NSCLC
07/10/2023
In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.
In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.
In a phase 3 study, biosimilar...
07/10/2023
Oncology

Advertisement

News

News
Proposed Bevacizumab Biosimilar BAT1706 Found Equivalent to Reference Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer
11/22/2023
According to a phase 3 trial, the proposed bevacizumab biosimilar BAT1706 was found equivalent to reference biosimilar for the treatment of patients with advanced nonsquamous non-small cell lung cancer.
According to a phase 3 trial, the proposed bevacizumab biosimilar BAT1706 was found equivalent to reference biosimilar for the treatment of patients with advanced nonsquamous non-small cell lung cancer.
According to a phase 3 trial,...
11/22/2023
Oncology
News
Pertuzumab Biosimilar QL1209 Demonstrated Equivalent Efficacy, Safety to Reference Pertuzumab Among Patients With HER2-Positive Breast Cancer
11/06/2023
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study,...
11/06/2023
Oncology
News
Bevacizumab Biosimilar Efficacy, Safety for Patients With Metastatic Colorectal Cancer
10/10/2023
According to real-world data, the bevacizumab biosimilar, bevacizumab-awwb, was found to be as effective and safe as the bevacizumab reference product for patients with metastatic colorectal cancer.
According to real-world data, the bevacizumab biosimilar, bevacizumab-awwb, was found to be as effective and safe as the bevacizumab reference product for patients with metastatic colorectal cancer.
According to real-world data,...
10/10/2023
Oncology
News
Docetaxel-PM Plus Trastuzumab Biosimilar Showed Antitumor Activity Among Patients With HER2-Positive Salivary Duct Carcinoma
10/10/2023
According to a phase 2 trial, combination docetaxel-PM and trastuzumab-pkrb demonstrated antitumor activity among patients with HER2-positive salivary duct carcinoma.
According to a phase 2 trial, combination docetaxel-PM and trastuzumab-pkrb demonstrated antitumor activity among patients with HER2-positive salivary duct carcinoma.
According to a phase 2 trial,...
10/10/2023
Oncology
News
Patients Report Satisfaction With Biosimilar Treatment, But Demonstrate Lack of Overall Knowledge
09/11/2023
According to a systematic review, patients are satisfied with biosimilar treatments but have limited knowledge about biosimilars, a lack of which can affect their perceptions of the clinical effects and regulation process.
According to a systematic review, patients are satisfied with biosimilar treatments but have limited knowledge about biosimilars, a lack of which can affect their perceptions of the clinical effects and regulation process.
According to a systematic...
09/11/2023
Oncology
News
Biosimilar Rituximab Plus CHOP Effective, Well-Tolerated Among Patients With Previously Untreated CD20-Positive DLBCL
09/07/2023
The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.
The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.
The rituximab biosimilar,...
09/07/2023
Oncology
News
Serplulimab Plus Bevacizumab Biosimilar Showed Efficacy, Safety Among Patients With Hepatocellular Carcinoma
09/05/2023
According to a results from a phase 2 study, serplulimab plus HLX04, a bevacizumab biosimilar, showed promising antitumor activity and manageable safety among patients with previously treated advanced hepatocellular carcinoma.
According to a results from a phase 2 study, serplulimab plus HLX04, a bevacizumab biosimilar, showed promising antitumor activity and manageable safety among patients with previously treated advanced hepatocellular carcinoma.
According to a results from a...
09/05/2023
Oncology
News
Trastuzumab Biosimilar Plus Paclitaxel Shows Promise for Patients With HER2-Positive Recurrent or Metastatic Urothelial Carcinoma
08/04/2023
In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.
In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.
In a phase 2 trial, the...
08/04/2023
Oncology
News
Bevacizumab Biosimilar Demonstrated Similar Efficacy, Safety as Reference Product Among Patients With Metastatic Colorectal Cancer
07/31/2023
The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.
The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.
The bevacizumab biosimilar,...
07/31/2023
Oncology
News
Bevacizumab Biosimilar Candidate TAB008 Comparable to Reference Bevacizumab for Patients With Locally Advanced, Metastatic EGFR Wild-Type Non-Squamous NSCLC
07/10/2023
In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.
In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.
In a phase 3 study, biosimilar...
07/10/2023
Oncology

Interactive Features

Quiz
Patients’ Perceptions of Biosimilars
10/23/2023
True or False: According to a systematic review, patients generally lack knowledge about biosimilars and rely on physicians, pharmacists, medicine agencies, academia, and patient associations for information.
True or False: According to a systematic review, patients generally lack knowledge about biosimilars and rely on physicians, pharmacists, medicine agencies, academia, and patient associations for information.
True or False: According to a...
10/23/2023
Oncology
Quiz
Originator vs Biosimilar Filgrastim for Hematologic Malignancies
06/12/2023
True or False: A retrospective study comparing originator filgrastim and biosimilar filgrastim showed no significant differences in CD34+ stem cell mobilization, the median time to achieve neutrophil and platelet engraftment, or safety...
True or False: A retrospective study comparing originator filgrastim and biosimilar filgrastim showed no significant differences in CD34+ stem cell mobilization, the median time to achieve neutrophil and platelet engraftment, or safety...
True or False: A retrospective...
06/12/2023
Oncology
Test Your Knowledge
Quiz: According to the FDA, What Makes a Drug a Biosimilar?
07/16/2019
What, according to the FDA, makes a biologic drug a biosimilar?
What, according to the FDA, makes a biologic drug a biosimilar?
What, according to the FDA,...
07/16/2019
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Proposed Bevacizumab Biosimilar BAT1706 Found Equivalent to Reference Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer
11/22/2023
According to a phase 3 trial, the proposed bevacizumab biosimilar BAT1706 was found equivalent to reference biosimilar for the treatment of patients with advanced nonsquamous non-small cell lung cancer.
According to a phase 3 trial, the proposed bevacizumab biosimilar BAT1706 was found equivalent to reference biosimilar for the treatment of patients with advanced nonsquamous non-small cell lung cancer.
According to a phase 3 trial,...
11/22/2023
Oncology
News
Pertuzumab Biosimilar QL1209 Demonstrated Equivalent Efficacy, Safety to Reference Pertuzumab Among Patients With HER2-Positive Breast Cancer
11/06/2023
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study, QL1209, a pertuzumab biosimilar, was found to have comparable efficacy, safety, and immunogenicity to the reference product among patients with HER2-positive breast cancer.
According to a phase 3 study,...
11/06/2023
Oncology
News
Bevacizumab Biosimilar Efficacy, Safety for Patients With Metastatic Colorectal Cancer
10/10/2023
According to real-world data, the bevacizumab biosimilar, bevacizumab-awwb, was found to be as effective and safe as the bevacizumab reference product for patients with metastatic colorectal cancer.
According to real-world data, the bevacizumab biosimilar, bevacizumab-awwb, was found to be as effective and safe as the bevacizumab reference product for patients with metastatic colorectal cancer.
According to real-world data,...
10/10/2023
Oncology
News
Docetaxel-PM Plus Trastuzumab Biosimilar Showed Antitumor Activity Among Patients With HER2-Positive Salivary Duct Carcinoma
10/10/2023
According to a phase 2 trial, combination docetaxel-PM and trastuzumab-pkrb demonstrated antitumor activity among patients with HER2-positive salivary duct carcinoma.
According to a phase 2 trial, combination docetaxel-PM and trastuzumab-pkrb demonstrated antitumor activity among patients with HER2-positive salivary duct carcinoma.
According to a phase 2 trial,...
10/10/2023
Oncology
News
Patients Report Satisfaction With Biosimilar Treatment, But Demonstrate Lack of Overall Knowledge
09/11/2023
According to a systematic review, patients are satisfied with biosimilar treatments but have limited knowledge about biosimilars, a lack of which can affect their perceptions of the clinical effects and regulation process.
According to a systematic review, patients are satisfied with biosimilar treatments but have limited knowledge about biosimilars, a lack of which can affect their perceptions of the clinical effects and regulation process.
According to a systematic...
09/11/2023
Oncology
News
Biosimilar Rituximab Plus CHOP Effective, Well-Tolerated Among Patients With Previously Untreated CD20-Positive DLBCL
09/07/2023
The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.
The rituximab biosimilar, SDZ-RTX, combined with a CHOP regimen was effective and well-tolerated as a frontline treatment for patients with diffuse large B-cell lymphoma (DLBCL), according to a real-world study.
The rituximab biosimilar,...
09/07/2023
Oncology
News
Serplulimab Plus Bevacizumab Biosimilar Showed Efficacy, Safety Among Patients With Hepatocellular Carcinoma
09/05/2023
According to a results from a phase 2 study, serplulimab plus HLX04, a bevacizumab biosimilar, showed promising antitumor activity and manageable safety among patients with previously treated advanced hepatocellular carcinoma.
According to a results from a phase 2 study, serplulimab plus HLX04, a bevacizumab biosimilar, showed promising antitumor activity and manageable safety among patients with previously treated advanced hepatocellular carcinoma.
According to a results from a...
09/05/2023
Oncology
News
Trastuzumab Biosimilar Plus Paclitaxel Shows Promise for Patients With HER2-Positive Recurrent or Metastatic Urothelial Carcinoma
08/04/2023
In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.
In a phase 2 trial, the trastuzumab biosimilar, trastuzumab-pkrb, plus paclitaxel demonstrated promising efficacy and manageable toxicity among patients with HER2-positive urothelial carcinoma.
In a phase 2 trial, the...
08/04/2023
Oncology
News
Bevacizumab Biosimilar Demonstrated Similar Efficacy, Safety as Reference Product Among Patients With Metastatic Colorectal Cancer
07/31/2023
The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.
The bevacizumab biosimilar, bevacizumab-awwb, was effective and well-tolerated in the first-line setting among patients with metastatic colorectal cancer.
The bevacizumab biosimilar,...
07/31/2023
Oncology
News
Bevacizumab Biosimilar Candidate TAB008 Comparable to Reference Bevacizumab for Patients With Locally Advanced, Metastatic EGFR Wild-Type Non-Squamous NSCLC
07/10/2023
In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.
In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.
In a phase 3 study, biosimilar...
07/10/2023
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement